CN100471836C - 托伐他汀钙晶型vi和vii - Google Patents

托伐他汀钙晶型vi和vii Download PDF

Info

Publication number
CN100471836C
CN100471836C CNB028150708A CN02815070A CN100471836C CN 100471836 C CN100471836 C CN 100471836C CN B028150708 A CNB028150708 A CN B028150708A CN 02815070 A CN02815070 A CN 02815070A CN 100471836 C CN100471836 C CN 100471836C
Authority
CN
China
Prior art keywords
calcium
reaction mixture
mixture
water
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028150708A
Other languages
English (en)
Chinese (zh)
Other versions
CN1537098A (zh
Inventor
M·S·雷迪
C·那加拉觉
G·斯里尼瓦苏卢
K·斯尼瓦斯
S·R·雷迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of CN1537098A publication Critical patent/CN1537098A/zh
Application granted granted Critical
Publication of CN100471836C publication Critical patent/CN100471836C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB028150708A 2001-07-30 2002-01-07 托伐他汀钙晶型vi和vii Expired - Fee Related CN100471836C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN620/MAS/01 2001-07-30
IN620MA2001 2001-07-30

Publications (2)

Publication Number Publication Date
CN1537098A CN1537098A (zh) 2004-10-13
CN100471836C true CN100471836C (zh) 2009-03-25

Family

ID=35160889

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028150708A Expired - Fee Related CN100471836C (zh) 2001-07-30 2002-01-07 托伐他汀钙晶型vi和vii

Country Status (19)

Country Link
EP (2) EP1414796A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005500351A (cg-RX-API-DMAC7.html)
KR (1) KR20040019043A (cg-RX-API-DMAC7.html)
CN (1) CN100471836C (cg-RX-API-DMAC7.html)
AU (1) AU2002255479B2 (cg-RX-API-DMAC7.html)
BG (1) BG108518A (cg-RX-API-DMAC7.html)
BR (1) BR0211488A (cg-RX-API-DMAC7.html)
CA (1) CA2454500C (cg-RX-API-DMAC7.html)
CZ (1) CZ2004126A3 (cg-RX-API-DMAC7.html)
EE (1) EE200400048A (cg-RX-API-DMAC7.html)
HR (1) HRP20040077A2 (cg-RX-API-DMAC7.html)
IL (2) IL159626A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000889A (cg-RX-API-DMAC7.html)
NO (1) NO20040390L (cg-RX-API-DMAC7.html)
NZ (1) NZ530785A (cg-RX-API-DMAC7.html)
PL (1) PL368647A1 (cg-RX-API-DMAC7.html)
RU (1) RU2304139C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003011826A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200400573B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
CN1535139A (zh) * 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2431068C (en) * 2000-12-27 2008-06-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of atorvastatin
PL372303A1 (en) * 2002-02-15 2005-07-11 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
JP4422488B2 (ja) 2002-02-19 2010-02-24 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
EP1572643A2 (en) * 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
EP1761489A1 (en) * 2004-03-17 2007-03-14 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
CA2560252C (en) 2004-03-17 2009-08-04 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
WO2006008091A2 (en) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2754932C (en) 2004-07-20 2014-04-01 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
TW200825092A (en) 2004-09-28 2008-06-16 Teva Pharma A method for reducing the level of AED in atorvastatin calcium sample
MX2007004722A (es) 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP2185527A2 (en) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
CN108157405B (zh) * 2018-02-06 2020-10-02 上海应用技术大学 一种灭蟑螂饵剂及其制备方法和应用
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1190955A (zh) * 1995-07-17 1998-08-19 沃尼尔·朗伯公司 结晶[R-(R',R')]-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-[(苯氨基)羰基
CN1190957A (zh) * 1995-07-17 1998-08-19 沃尼尔·朗伯公司 (R-(R*,R*)-2-(4-氟苯基)-β-δ-二羟基-5-(1-甲基-乙基)-3-苯基-4-[(苯基氨基)羰基]-1H-吡咯-1-庚酸半钙盐的Ⅲ型结晶

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5929156A (en) 1997-05-02 1999-07-27 J.M. Huber Corporation Silica product for use in elastomers
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
SI1535613T1 (sl) * 1999-11-17 2010-12-31 Teva Pharma Postopek za pripravo polimorfne oblike atorvastatin kalcija
CN1535139A (zh) * 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
HRP20030454A2 (en) * 2000-11-16 2005-10-31 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-(3,6-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2431068C (en) * 2000-12-27 2008-06-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of atorvastatin
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1190955A (zh) * 1995-07-17 1998-08-19 沃尼尔·朗伯公司 结晶[R-(R',R')]-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-[(苯氨基)羰基
CN1190957A (zh) * 1995-07-17 1998-08-19 沃尼尔·朗伯公司 (R-(R*,R*)-2-(4-氟苯基)-β-δ-二羟基-5-(1-甲基-乙基)-3-苯基-4-[(苯基氨基)羰基]-1H-吡咯-1-庚酸半钙盐的Ⅲ型结晶

Also Published As

Publication number Publication date
CA2454500C (en) 2009-11-10
HRP20040077A2 (en) 2004-06-30
EE200400048A (et) 2004-04-15
RU2004103470A (ru) 2005-06-20
NO20040390L (no) 2004-01-29
EP1414796A1 (en) 2004-05-06
KR20040019043A (ko) 2004-03-04
NZ530785A (en) 2005-10-28
BR0211488A (pt) 2004-08-17
CN1537098A (zh) 2004-10-13
JP2005500351A (ja) 2005-01-06
WO2003011826A1 (en) 2003-02-13
RU2304139C2 (ru) 2007-08-10
CA2454500A1 (en) 2003-02-13
PL368647A1 (en) 2005-04-04
AU2002255479B2 (en) 2008-09-11
IL159626A0 (en) 2004-06-01
MXPA04000889A (es) 2004-06-03
CZ2004126A3 (cs) 2004-12-15
IL159626A (en) 2013-04-30
BG108518A (en) 2004-08-31
EP2292600A1 (en) 2011-03-09
ZA200400573B (en) 2005-05-11

Similar Documents

Publication Publication Date Title
CA2454500C (en) Crystalline forms vi and vii of atorvastatin calcium
KR100389518B1 (ko) 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴)
AU2002255479A1 (en) Crystalline forms VI and VII of atorvastatin clacium
AU725368B2 (en) Form III crystalline (R-(R*,R*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5- (1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H- pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
JP2003201236A (ja) 高コレステロール血症治療用の医薬組成物
US20040242899A1 (en) Crystalline forms VI and VII of atrovastatin calcium
WO2005090301B1 (en) Crystalline form of atorvastatin hemi calcium
EP2420488A1 (en) Novel crystalline form of atorvastatin hemi-calcium salt, hydrate thereof, and method of producing the same
TW200844093A (en) Atorvastatin strontium salt and pharmaceutical composition comprising same
CN101492405B (zh) 阿伐他汀钙的制备方法
WO2008108572A1 (en) Novel crystal forms of pyrrolylheptanoic acid derivatives
WO2006048894A1 (en) Novel crystalline forms of atorvastatin calcium and processes for preparing them.
EP0848704B1 (en) Form iii crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
KR101050722B1 (ko) 무정형 아토르바스타틴 칼슘염의 제조방법
WO2005014541A1 (en) Novel antihypercholesterolemic compound
NZ579736A (en) Crystalline forms of atorvastatin 4-(nitrooxy) butyl ester
JP2003073354A6 (ja) 形態IIIの結晶性の(R−(R*,R*))−2−(4−フルオロフェニル)−β,δ−ジヒドロキシ−5−(1−メチル−エチル)−3−フェニル−4−((フェニルアミノ)カルボニル)−1H−ピロール−1−ヘプタン酸ヘミカルシウム塩(アトルバスタチン)
JP2003073354A (ja) 形態IIIの結晶性の(R−(R*,R*))−2−(4−フルオロフェニル)−β,δ−ジヒドロキシ−5−(1−メチル−エチル)−3−フェニル−4−((フェニルアミノ)カルボニル)−1H−ピロール−1−ヘプタン酸ヘミカルシウム塩(アトルバスタチン)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090325

Termination date: 20120107